These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20211479)

  • 1. Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen.
    Neirinckx E; Vervaet C; De Boever S; Remon JP; Gommeren K; Daminet S; De Backer P; Croubels S
    Res Vet Sci; 2010 Aug; 89(1):113-9. PubMed ID: 20211479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen.
    Neirinckx E; Croubels S; De Boever S; Remon JP; Bosmans T; Daminet S; De Backer P; Vervaet C
    Res Vet Sci; 2011 Dec; 91(3):415-21. PubMed ID: 20961590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
    Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
    Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
    Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
    Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration.
    Sárközy G; Semjén G; Laczay P
    Vet J; 2004 Nov; 168(3):312-6. PubMed ID: 15501149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the oral bioavailability and tissue disposition of monensin and salinomycin in chickens and turkeys.
    Henri J; Maurice R; Postollec G; Dubreil-Cheneau E; Roudaut B; Laurentie M; Sanders P
    J Vet Pharmacol Ther; 2012 Feb; 35(1):73-81. PubMed ID: 21615753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of dirlotapide in the dog.
    Merritt DA; Lynch MP; King VL
    J Vet Pharmacol Ther; 2007 Aug; 30 Suppl 1():24-32. PubMed ID: 17567512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
    Perera MA; Yin D; Wu D; Chan KK; Miller DD; Dalton J
    Drug Metab Dispos; 2006 Oct; 34(10):1713-21. PubMed ID: 16815963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of oral bioavailability of paracetamol by tolmetin in rat.
    Sabater J; Peraire C; Obach R; Moreno J; Domenech J
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():61-5. PubMed ID: 1820937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of the Ussing chamber technique for the determination of in vitro jejunal permeability of passively absorbed compounds in different animal species.
    Neirinckx E; Vervaet C; Michiels J; De Smet S; Van den Broeck W; Remon JP; De Backer P; Croubels S
    J Vet Pharmacol Ther; 2011 Jun; 34(3):290-7. PubMed ID: 21492193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.